Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.40 |
| ▸ | ITGAL | P20701 | 4/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532352 | 0.84 | ITGB2 (0.47) | GAASMN1; SMN2RETSMOHRH1 | |
| SCHEMBL12991337 | 0.84 | ALDH1A1 (0.45) | GAASMN1; SMN2RETSMOHRH1 | |
| SCHEMBL3548025 | 0.82 | GAA (0.45) | GAASMN1; SMN2RETHRH1SLC6A15 | |
| SCHEMBL13439444 | 0.82 | GAA (0.46) | GAASMN1; SMN2RETHRH3FAAH | |
| SCHEMBL13404662 | 0.82 | GAA (0.46) | GAASMN1; SMN2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL12991321 | 0.80 | MAPT (0.46) | GAASMN1; SMN2HSD17B10FAAHSMARCA2 | |
| SCHEMBL3532899 | 0.80 | SMN1; SMN2 (0.47) | GAASMN1; SMN2RETSMOHSD17B10 | |
| SCHEMBL12781798 | 0.76 | SMN1; SMN2 (0.53) | GAASMN1; SMN2HSD17B10FAAHKDM4E | |
| SCHEMBL3207639 | 0.75 | GAA (0.43) | GAASMN1; SMN2HSD17B10SMARCA2SMARCA4 | |
| SCHEMBL12991318 | 0.75 | LRRK2 (0.49) | RETSMOHSD17B10ITGB2ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683065-B2 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683065-B2 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683065-B2 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070082889-A1 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-12 | — | — | US | disclosed |
| US-20070082889-A1 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-12 | — | — | US | disclosed |
| US-20070082889-A1 | Pyridines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082889-A1 | Pyridines useful as modulators of ion channels | KCNH2, KCNQ1, KCNQ2 | GAA 2521/4885SMN1; SMN2 901/4885RET 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.